Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome

Lucrezia Laterza; Gianluca Ianiro; Iolanda Scoleri; Rosario Landi; Franco Scaldaferri; Eleonora Gaetani; Mariachiara Campanale; Antonio Gasbarrini

doi:10.1517/14656566.2015.1007951

Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome

Lucrezia Laterza, Gianluca Ianiro, Iolanda Scoleri, Rosario Landi, Franco Scaldaferri, Eleonora Gaetani, Mariachiara Campanale, Antonio Gasbarrini

Risultato della ricerca: Contributo in rivista › Articolo in rivista

12 Citazioni (Scopus)

Abstract

Rifaximin is a non-absorbable, semisynthetic antibiotic that acts as an inhibitor of bacterial RNA synthesis, with a broad spectrum of antibacterial activity. Due to its poor absorption, rifaximin has an increased exposure to the intestine, thus it is suitable for the treatment of many gastrointestinal (GI) diseases. In irritable bowel syndrome (IBS) pathogenesis, gut microbiota impairment may play a major role. The possibility of modulating intestinal bacteria using antibiotics, in particular, rifaximin, has been demonstrated to improve IBS symptoms in non-constipation subtypes of IBS.

Lingua originale	English
pagine (da-a)	607-615
Numero di pagine	9
Rivista	Expert Opinion on Pharmacotherapy
Volume	16
DOI	https://doi.org/10.1517/14656566.2015.1007951
Stato di pubblicazione	Pubblicato - 2015

Keywords

Animals
Anti-Bacterial Agents
Diarrhea
Drug Interactions
Drug Resistance, Bacterial
Humans
Irritable Bowel Syndrome
Rifamycins
antibiotics
gut microbiota
irritable bowel syndrome
pharmacokinetic
rifaximin

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1517/14656566.2015.1007951

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{e3b785c1bd3743eb8b842f7c81d64295,

title = "Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome",

abstract = "Rifaximin is a non-absorbable, semisynthetic antibiotic that acts as an inhibitor of bacterial RNA synthesis, with a broad spectrum of antibacterial activity. Due to its poor absorption, rifaximin has an increased exposure to the intestine, thus it is suitable for the treatment of many gastrointestinal (GI) diseases. In irritable bowel syndrome (IBS) pathogenesis, gut microbiota impairment may play a major role. The possibility of modulating intestinal bacteria using antibiotics, in particular, rifaximin, has been demonstrated to improve IBS symptoms in non-constipation subtypes of IBS.",

keywords = "Animals, Anti-Bacterial Agents, Diarrhea, Drug Interactions, Drug Resistance, Bacterial, Humans, Irritable Bowel Syndrome, Rifamycins, antibiotics, gut microbiota, irritable bowel syndrome, pharmacokinetic, rifaximin, Animals, Anti-Bacterial Agents, Diarrhea, Drug Interactions, Drug Resistance, Bacterial, Humans, Irritable Bowel Syndrome, Rifamycins, antibiotics, gut microbiota, irritable bowel syndrome, pharmacokinetic, rifaximin",

author = "Lucrezia Laterza and Gianluca Ianiro and Iolanda Scoleri and Rosario Landi and Franco Scaldaferri and Eleonora Gaetani and Mariachiara Campanale and Antonio Gasbarrini",

year = "2015",

doi = "10.1517/14656566.2015.1007951",

language = "English",

volume = "16",

pages = "607--615",

journal = "Expert Opinion on Pharmacotherapy",

issn = "1465-6566",

publisher = "-London United Kingdom:Informa Healthcare -London , United Kingdom: Ashley Publications Limited",

}

TY - JOUR

T1 - Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome

AU - Laterza, Lucrezia

AU - Ianiro, Gianluca

AU - Scoleri, Iolanda

AU - Landi, Rosario

AU - Scaldaferri, Franco

AU - Gaetani, Eleonora

AU - Campanale, Mariachiara

AU - Gasbarrini, Antonio

PY - 2015

Y1 - 2015

N2 - Rifaximin is a non-absorbable, semisynthetic antibiotic that acts as an inhibitor of bacterial RNA synthesis, with a broad spectrum of antibacterial activity. Due to its poor absorption, rifaximin has an increased exposure to the intestine, thus it is suitable for the treatment of many gastrointestinal (GI) diseases. In irritable bowel syndrome (IBS) pathogenesis, gut microbiota impairment may play a major role. The possibility of modulating intestinal bacteria using antibiotics, in particular, rifaximin, has been demonstrated to improve IBS symptoms in non-constipation subtypes of IBS.

AB - Rifaximin is a non-absorbable, semisynthetic antibiotic that acts as an inhibitor of bacterial RNA synthesis, with a broad spectrum of antibacterial activity. Due to its poor absorption, rifaximin has an increased exposure to the intestine, thus it is suitable for the treatment of many gastrointestinal (GI) diseases. In irritable bowel syndrome (IBS) pathogenesis, gut microbiota impairment may play a major role. The possibility of modulating intestinal bacteria using antibiotics, in particular, rifaximin, has been demonstrated to improve IBS symptoms in non-constipation subtypes of IBS.

KW - Animals

KW - Anti-Bacterial Agents

KW - Diarrhea

KW - Drug Interactions

KW - Drug Resistance, Bacterial

KW - Humans

KW - Irritable Bowel Syndrome

KW - Rifamycins

KW - antibiotics

KW - gut microbiota

KW - irritable bowel syndrome

KW - pharmacokinetic

KW - rifaximin

KW - Animals

KW - Anti-Bacterial Agents

KW - Diarrhea

KW - Drug Interactions

KW - Drug Resistance, Bacterial

KW - Humans

KW - Irritable Bowel Syndrome

KW - Rifamycins

KW - antibiotics

KW - gut microbiota

KW - irritable bowel syndrome

KW - pharmacokinetic

KW - rifaximin

UR - http://hdl.handle.net/10807/68311

U2 - 10.1517/14656566.2015.1007951

DO - 10.1517/14656566.2015.1007951

M3 - Article

SN - 1465-6566

VL - 16

SP - 607

EP - 615

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

ER -

Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo